Clinical outcomes from EMERALD trial: A phase I evaluating ultra-hypofractionated MR-Guided Adaptive SABR (SMART) for localized pancreatic cancer
Mukherjee S., Moreno-Olmedo E., Teoh S., Swan L., Ooms A., Massa MS., Qiao Y., George B., Nugent K., Levy S., Owens R., Sabharwal A., Camilleri P., Robinson M., Good J., Maughan T.